NO20065074L - Nye orale formuleringer av ospemifen. - Google Patents
Nye orale formuleringer av ospemifen.Info
- Publication number
- NO20065074L NO20065074L NO20065074A NO20065074A NO20065074L NO 20065074 L NO20065074 L NO 20065074L NO 20065074 A NO20065074 A NO 20065074A NO 20065074 A NO20065074 A NO 20065074A NO 20065074 L NO20065074 L NO 20065074L
- Authority
- NO
- Norway
- Prior art keywords
- ospemifene
- oral formulations
- new oral
- pharmaceutically acceptable
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det beskrives en flytende eller halvfast peroral medikamentformulering, omfattende en terapeutisk aktiv forbindelse med formel (I) eller en geometrisk isomer, en stereoisomer, et farmasøytisk akseptabelt salt, en ester av denne eller en metabolitt av denne, i kombinasjon med en farmasøytisk akseptabel bærer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56752504P | 2004-05-04 | 2004-05-04 | |
PCT/FI2005/000131 WO2005105052A1 (en) | 2004-05-04 | 2005-03-02 | Novel oral formulations of ospemifene |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20065074L true NO20065074L (no) | 2006-11-29 |
NO338736B1 NO338736B1 (no) | 2016-10-17 |
Family
ID=35241411
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065074A NO338736B1 (no) | 2004-05-04 | 2006-11-03 | Nye flytende orale formuleringer av ospemifen |
NO20161206A NO343582B1 (no) | 2004-05-04 | 2016-07-21 | Oral medikamentformulering omfattende ospemifen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20161206A NO343582B1 (no) | 2004-05-04 | 2016-07-21 | Oral medikamentformulering omfattende ospemifen |
Country Status (19)
Country | Link |
---|---|
US (1) | USRE47316E1 (no) |
EP (2) | EP2275098B1 (no) |
JP (3) | JP5497983B2 (no) |
KR (1) | KR101278934B1 (no) |
CN (1) | CN1950071A (no) |
AU (2) | AU2005237274B2 (no) |
BR (1) | BRPI0510465B8 (no) |
CA (1) | CA2565134C (no) |
CY (2) | CY1113280T1 (no) |
DK (2) | DK2275098T3 (no) |
ES (2) | ES2391626T3 (no) |
HK (1) | HK1151227A1 (no) |
MX (1) | MXPA06012758A (no) |
NO (2) | NO338736B1 (no) |
PL (2) | PL1742618T3 (no) |
PT (2) | PT1742618E (no) |
RU (1) | RU2006142706A (no) |
SI (2) | SI2275098T1 (no) |
WO (1) | WO2005105052A1 (no) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4588791B2 (ja) * | 2007-02-16 | 2010-12-01 | あすか製薬株式会社 | 微粒子油性懸濁液を含む医薬組成物 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117121A (en) | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
JPH0616556A (ja) * | 1992-07-02 | 1994-01-25 | Yoshitomi Pharmaceut Ind Ltd | 難溶性薬物含有製剤 |
JPH07196483A (ja) | 1993-11-25 | 1995-08-01 | Taisho Pharmaceut Co Ltd | 経口吸収性を改善した製剤組成物 |
JPH07165610A (ja) | 1993-12-15 | 1995-06-27 | Hiroshi Maeda | 血圧制御剤 |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FI100692B (fi) | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
CA2195623A1 (en) * | 1994-07-22 | 1996-02-08 | Rajeev D. Gokhale | Self-emulsifying drug delivery system |
GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5597582A (en) * | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
FI101305B (fi) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatse piini-johdannaiset ja niiden käyttö diagnostiikassa |
CA2282411A1 (en) * | 1997-02-27 | 1998-09-03 | Nippon Shinyaku Co., Ltd. | Fat emulsion for oral administration |
US6525084B2 (en) | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6838484B2 (en) | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
FI20010115A0 (fi) * | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
ATE498408T1 (de) | 2001-08-10 | 2011-03-15 | Takeda Pharmaceutical | Gnrh-agonistische kombinationsmittel |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
JP2004045373A (ja) | 2002-05-21 | 2004-02-12 | Tanita Corp | 電気化学式センサ |
UA79797C2 (en) | 2002-06-06 | 2007-07-25 | Hormos Medical Corp | Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
WO2006052921A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
-
2005
- 2005-03-02 SI SI200531576T patent/SI2275098T1/sl unknown
- 2005-03-02 EP EP10179959A patent/EP2275098B1/en active Active
- 2005-03-02 ES ES10179959T patent/ES2391626T3/es active Active
- 2005-03-02 DK DK10179959.1T patent/DK2275098T3/da active
- 2005-03-02 CA CA2565134A patent/CA2565134C/en active Active
- 2005-03-02 SI SI200531581T patent/SI1742618T1/sl unknown
- 2005-03-02 PT PT05717258T patent/PT1742618E/pt unknown
- 2005-03-02 KR KR1020067022870A patent/KR101278934B1/ko active IP Right Grant
- 2005-03-02 ES ES05717258T patent/ES2392344T3/es active Active
- 2005-03-02 BR BRPI0510465A patent/BRPI0510465B8/pt not_active IP Right Cessation
- 2005-03-02 PL PL05717258T patent/PL1742618T3/pl unknown
- 2005-03-02 AU AU2005237274A patent/AU2005237274B2/en not_active Ceased
- 2005-03-02 DK DK05717258.7T patent/DK1742618T3/da active
- 2005-03-02 EP EP05717258A patent/EP1742618B1/en active Active
- 2005-03-02 RU RU2006142706/15A patent/RU2006142706A/ru not_active Application Discontinuation
- 2005-03-02 WO PCT/FI2005/000131 patent/WO2005105052A1/en active Application Filing
- 2005-03-02 MX MXPA06012758A patent/MXPA06012758A/es active IP Right Grant
- 2005-03-02 PT PT10179959T patent/PT2275098E/pt unknown
- 2005-03-02 CN CNA2005800140082A patent/CN1950071A/zh active Pending
- 2005-03-02 PL PL10179959T patent/PL2275098T3/pl unknown
- 2005-03-02 JP JP2007512233A patent/JP5497983B2/ja active Active
-
2006
- 2006-11-03 NO NO20065074A patent/NO338736B1/no not_active IP Right Cessation
-
2011
- 2011-05-16 AU AU2011202264A patent/AU2011202264B8/en not_active Ceased
- 2011-05-27 HK HK11105314.5A patent/HK1151227A1/xx not_active IP Right Cessation
-
2012
- 2012-05-02 JP JP2012105131A patent/JP5643255B2/ja active Active
- 2012-08-09 CY CY20121100717T patent/CY1113280T1/el unknown
- 2012-09-13 CY CY20121100833T patent/CY1113284T1/el unknown
-
2014
- 2014-06-03 JP JP2014114727A patent/JP5834111B2/ja active Active
-
2016
- 2016-06-23 US US15/191,316 patent/USRE47316E1/en active Active
- 2016-07-21 NO NO20161206A patent/NO343582B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005027540D1 (de) | Feste formulierungen von ospemifen | |
RU2445312C2 (ru) | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR | |
NO20082181L (no) | Formuleringer av Fispemifen | |
CY1106150T1 (el) | Μεθοδοι παρασκευης οπτικως καθαρης (r)- και (s)-διδεσμεθυλοσιβουτραμινης | |
LTC1713458I2 (lt) | Ospemifeno bioaktyvumo padidinimo būdas | |
HRP20080052T3 (en) | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation | |
RU2011138962A (ru) | Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1 | |
MX2010004232A (es) | Compuesto de indolina de pirimidilo. | |
NO20064297L (no) | Aminoalkoholforbindelse | |
NO20055631L (no) | Doseringsform inneholdende pantoprazol som aktiv ingrediens | |
EA200000700A2 (ru) | НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ | |
NI201200170A (es) | Formulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg - coa reductasa e irbesartan | |
ES2573539T3 (es) | Inhibidor de la cristalización y su uso en cápsulas de gelatina | |
NO20063662L (no) | Benzimidazolderivater | |
NO20055601L (no) | Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer | |
SE0401655D0 (sv) | New compounds | |
NO20065074L (no) | Nye orale formuleringer av ospemifen. | |
UY28457A1 (es) | Nueva composición | |
CR10506A (es) | Derivados de acido fenilacetico | |
NO20076251L (no) | Nye DHA derivater og deres anvendelse som medikamenter | |
NO20054319L (no) | Neovaskulaseringspromoter | |
RU2446158C2 (ru) | Замещенные изоиндолы в качестве ингибиторов васе и их применение | |
RU2007115741A (ru) | Производные 4,6-диметил-2,3-дигидро-1н-пиразоло[4,3-с]пиридин-3-онов и эфиры 2,6-диметил-4-фенил-гидразиноникотиновых кислот в качестве промежуточных продуктов для их синтеза, обладающие антидепрессантной и анксиолитической активностью | |
ITMI20032020A1 (it) | Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici | |
TH54911B (th) | สูตรปลดปล่อยที่ควบคุม |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: QUATRX PHARMACEUTICALS, US |
|
MM1K | Lapsed by not paying the annual fees |